Cargando…
Re-Irradiation for Recurrent Cervical Cancer: A State-of-the-Art Review
The recurrence rate of cervical cancer after primary treatment can reach 60%, and a poor prognosis is reported in most cases. Treatment options for the recurrence of cervical cancer mainly depend on the prior treatment regimen and the location of recurrent lesions. Re-irradiation is still considered...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331513/ https://www.ncbi.nlm.nih.gov/pubmed/35892987 http://dx.doi.org/10.3390/curroncol29080418 |
_version_ | 1784758422622699520 |
---|---|
author | Shen, Zongyan Qu, Ang Jiang, Ping Jiang, Yuliang Sun, Haitao Wang, Junjie |
author_facet | Shen, Zongyan Qu, Ang Jiang, Ping Jiang, Yuliang Sun, Haitao Wang, Junjie |
author_sort | Shen, Zongyan |
collection | PubMed |
description | The recurrence rate of cervical cancer after primary treatment can reach 60%, and a poor prognosis is reported in most cases. Treatment options for the recurrence of cervical cancer mainly depend on the prior treatment regimen and the location of recurrent lesions. Re-irradiation is still considered as a clinical challenge, owing to a high incidence of toxicity, especially in in-field recurrence within a short period of time. Recent advances in radiotherapy have preliminarily revealed encouraging outcomes of re-irradiation. Several centers have concentrasted on stereotactic body radiation therapy (SBRT) for the treatment of well-selected cases. Meanwhile, as the image-guiding techniques become more precise, a better dose profile can also be achieved in brachytherapy, including high-dose-rate interstitial brachytherapy (HDR-ISBT) and permanent radioactive seed implantation (PRSI). These treatment modalities have shown promising efficacy with a tolerable toxicity, providing further treatment options for recurrent cervical cancer. However, it is highly unlikely to draw a definite conclusion from all of those studies due to the large heterogeneity among them and the lack of large-scale prospective studies. This study mainly reviews and summarizes the progress of re-irradiation for recurrent cervical cancer in recent years, in order to provide potential treatment regimens for the management of re-irradiation. |
format | Online Article Text |
id | pubmed-9331513 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93315132022-07-29 Re-Irradiation for Recurrent Cervical Cancer: A State-of-the-Art Review Shen, Zongyan Qu, Ang Jiang, Ping Jiang, Yuliang Sun, Haitao Wang, Junjie Curr Oncol Review The recurrence rate of cervical cancer after primary treatment can reach 60%, and a poor prognosis is reported in most cases. Treatment options for the recurrence of cervical cancer mainly depend on the prior treatment regimen and the location of recurrent lesions. Re-irradiation is still considered as a clinical challenge, owing to a high incidence of toxicity, especially in in-field recurrence within a short period of time. Recent advances in radiotherapy have preliminarily revealed encouraging outcomes of re-irradiation. Several centers have concentrasted on stereotactic body radiation therapy (SBRT) for the treatment of well-selected cases. Meanwhile, as the image-guiding techniques become more precise, a better dose profile can also be achieved in brachytherapy, including high-dose-rate interstitial brachytherapy (HDR-ISBT) and permanent radioactive seed implantation (PRSI). These treatment modalities have shown promising efficacy with a tolerable toxicity, providing further treatment options for recurrent cervical cancer. However, it is highly unlikely to draw a definite conclusion from all of those studies due to the large heterogeneity among them and the lack of large-scale prospective studies. This study mainly reviews and summarizes the progress of re-irradiation for recurrent cervical cancer in recent years, in order to provide potential treatment regimens for the management of re-irradiation. MDPI 2022-07-25 /pmc/articles/PMC9331513/ /pubmed/35892987 http://dx.doi.org/10.3390/curroncol29080418 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Shen, Zongyan Qu, Ang Jiang, Ping Jiang, Yuliang Sun, Haitao Wang, Junjie Re-Irradiation for Recurrent Cervical Cancer: A State-of-the-Art Review |
title | Re-Irradiation for Recurrent Cervical Cancer: A State-of-the-Art Review |
title_full | Re-Irradiation for Recurrent Cervical Cancer: A State-of-the-Art Review |
title_fullStr | Re-Irradiation for Recurrent Cervical Cancer: A State-of-the-Art Review |
title_full_unstemmed | Re-Irradiation for Recurrent Cervical Cancer: A State-of-the-Art Review |
title_short | Re-Irradiation for Recurrent Cervical Cancer: A State-of-the-Art Review |
title_sort | re-irradiation for recurrent cervical cancer: a state-of-the-art review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331513/ https://www.ncbi.nlm.nih.gov/pubmed/35892987 http://dx.doi.org/10.3390/curroncol29080418 |
work_keys_str_mv | AT shenzongyan reirradiationforrecurrentcervicalcancerastateoftheartreview AT quang reirradiationforrecurrentcervicalcancerastateoftheartreview AT jiangping reirradiationforrecurrentcervicalcancerastateoftheartreview AT jiangyuliang reirradiationforrecurrentcervicalcancerastateoftheartreview AT sunhaitao reirradiationforrecurrentcervicalcancerastateoftheartreview AT wangjunjie reirradiationforrecurrentcervicalcancerastateoftheartreview |